Pentoxifylline

Joju George, Peter W. Abel

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Pentoxifylline is a synthetic dimethylxanthine derivative structurally related to the methylxanthine derivatives theophylline, caffeine, and theobromine. Pentoxifylline differs structurally from these other agents by the presence of a 5-oxohexyl group at position 1. Pentoxifylline is usually classified as a vasodilator. However, its primary action appears to be a reduction in blood viscosity by increasing erythrocyte deformability, inhibiting platelet adhesion and aggregation, reducing plasma fibrinogen, and increasing fibrinolytic activity. Pentoxifylline is reported to increase blood flow to ischemic tissues and improve tissue oxygenation in patients with peripheral vascular disease. In the central nervous system, pentoxifylline can increase oxygen tension in both the cerebral cortex and in the cerebrospinal fluid. Pentoxifylline has also been shown to increase leukocyte deformability, inhibit neutrophil adhesion and activation and inhibit production of the cytokine, tumor necrosis factor-alpha (TNF). Pentoxifylline is indicated in the treatment of intermittent claudication associated with peripheral vascular diseases (i.e., chronic occlusive arterial disease of the extremities). Although pentoxifylline can improve function and reduce symptoms of these diseases, it is not intended to replace more definitive treatments, such as surgical bypass or removal of arterial obstructions (Physicians desk reference, 2005).It has also been suggested to be useful in the treatment of many other conditions including acute and chronic cerebrovascular insufficiency associated with ischemic stroke, psychopathological symptoms associated with aging, transient ischemic attacks.

Original languageEnglish
Title of host publicationxPharm: The Comprehensive Pharmacology Reference
PublisherElsevier Inc.
Pages1-18
Number of pages18
ISBN (Print)9780080552323
DOIs
StatePublished - 2011

Fingerprint

Pentoxifylline
Peripheral Vascular Diseases
Theobromine
Erythrocyte Deformability
Cerebrovascular Disorders
Intermittent Claudication
Arterial Occlusive Diseases
Neutrophil Activation
Blood Viscosity
Transient Ischemic Attack
Theophylline
Caffeine
Vasodilator Agents
Platelet Aggregation
Cerebral Cortex
Fibrinogen
Cerebrospinal Fluid
Leukocytes
Therapeutics
Extremities

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

George, J., & Abel, P. W. (2011). Pentoxifylline. In xPharm: The Comprehensive Pharmacology Reference (pp. 1-18). Elsevier Inc.. https://doi.org/10.1016/B978-008055232-3.63921-2

Pentoxifylline. / George, Joju; Abel, Peter W.

xPharm: The Comprehensive Pharmacology Reference. Elsevier Inc., 2011. p. 1-18.

Research output: Chapter in Book/Report/Conference proceedingChapter

George, J & Abel, PW 2011, Pentoxifylline. in xPharm: The Comprehensive Pharmacology Reference. Elsevier Inc., pp. 1-18. https://doi.org/10.1016/B978-008055232-3.63921-2
George J, Abel PW. Pentoxifylline. In xPharm: The Comprehensive Pharmacology Reference. Elsevier Inc. 2011. p. 1-18 https://doi.org/10.1016/B978-008055232-3.63921-2
George, Joju ; Abel, Peter W. / Pentoxifylline. xPharm: The Comprehensive Pharmacology Reference. Elsevier Inc., 2011. pp. 1-18
@inbook{b93220271bc8461e9e5f3d3c94663232,
title = "Pentoxifylline",
abstract = "Pentoxifylline is a synthetic dimethylxanthine derivative structurally related to the methylxanthine derivatives theophylline, caffeine, and theobromine. Pentoxifylline differs structurally from these other agents by the presence of a 5-oxohexyl group at position 1. Pentoxifylline is usually classified as a vasodilator. However, its primary action appears to be a reduction in blood viscosity by increasing erythrocyte deformability, inhibiting platelet adhesion and aggregation, reducing plasma fibrinogen, and increasing fibrinolytic activity. Pentoxifylline is reported to increase blood flow to ischemic tissues and improve tissue oxygenation in patients with peripheral vascular disease. In the central nervous system, pentoxifylline can increase oxygen tension in both the cerebral cortex and in the cerebrospinal fluid. Pentoxifylline has also been shown to increase leukocyte deformability, inhibit neutrophil adhesion and activation and inhibit production of the cytokine, tumor necrosis factor-alpha (TNF). Pentoxifylline is indicated in the treatment of intermittent claudication associated with peripheral vascular diseases (i.e., chronic occlusive arterial disease of the extremities). Although pentoxifylline can improve function and reduce symptoms of these diseases, it is not intended to replace more definitive treatments, such as surgical bypass or removal of arterial obstructions (Physicians desk reference, 2005).It has also been suggested to be useful in the treatment of many other conditions including acute and chronic cerebrovascular insufficiency associated with ischemic stroke, psychopathological symptoms associated with aging, transient ischemic attacks.",
author = "Joju George and Abel, {Peter W.}",
year = "2011",
doi = "10.1016/B978-008055232-3.63921-2",
language = "English",
isbn = "9780080552323",
pages = "1--18",
booktitle = "xPharm: The Comprehensive Pharmacology Reference",
publisher = "Elsevier Inc.",
address = "United States",

}

TY - CHAP

T1 - Pentoxifylline

AU - George, Joju

AU - Abel, Peter W.

PY - 2011

Y1 - 2011

N2 - Pentoxifylline is a synthetic dimethylxanthine derivative structurally related to the methylxanthine derivatives theophylline, caffeine, and theobromine. Pentoxifylline differs structurally from these other agents by the presence of a 5-oxohexyl group at position 1. Pentoxifylline is usually classified as a vasodilator. However, its primary action appears to be a reduction in blood viscosity by increasing erythrocyte deformability, inhibiting platelet adhesion and aggregation, reducing plasma fibrinogen, and increasing fibrinolytic activity. Pentoxifylline is reported to increase blood flow to ischemic tissues and improve tissue oxygenation in patients with peripheral vascular disease. In the central nervous system, pentoxifylline can increase oxygen tension in both the cerebral cortex and in the cerebrospinal fluid. Pentoxifylline has also been shown to increase leukocyte deformability, inhibit neutrophil adhesion and activation and inhibit production of the cytokine, tumor necrosis factor-alpha (TNF). Pentoxifylline is indicated in the treatment of intermittent claudication associated with peripheral vascular diseases (i.e., chronic occlusive arterial disease of the extremities). Although pentoxifylline can improve function and reduce symptoms of these diseases, it is not intended to replace more definitive treatments, such as surgical bypass or removal of arterial obstructions (Physicians desk reference, 2005).It has also been suggested to be useful in the treatment of many other conditions including acute and chronic cerebrovascular insufficiency associated with ischemic stroke, psychopathological symptoms associated with aging, transient ischemic attacks.

AB - Pentoxifylline is a synthetic dimethylxanthine derivative structurally related to the methylxanthine derivatives theophylline, caffeine, and theobromine. Pentoxifylline differs structurally from these other agents by the presence of a 5-oxohexyl group at position 1. Pentoxifylline is usually classified as a vasodilator. However, its primary action appears to be a reduction in blood viscosity by increasing erythrocyte deformability, inhibiting platelet adhesion and aggregation, reducing plasma fibrinogen, and increasing fibrinolytic activity. Pentoxifylline is reported to increase blood flow to ischemic tissues and improve tissue oxygenation in patients with peripheral vascular disease. In the central nervous system, pentoxifylline can increase oxygen tension in both the cerebral cortex and in the cerebrospinal fluid. Pentoxifylline has also been shown to increase leukocyte deformability, inhibit neutrophil adhesion and activation and inhibit production of the cytokine, tumor necrosis factor-alpha (TNF). Pentoxifylline is indicated in the treatment of intermittent claudication associated with peripheral vascular diseases (i.e., chronic occlusive arterial disease of the extremities). Although pentoxifylline can improve function and reduce symptoms of these diseases, it is not intended to replace more definitive treatments, such as surgical bypass or removal of arterial obstructions (Physicians desk reference, 2005).It has also been suggested to be useful in the treatment of many other conditions including acute and chronic cerebrovascular insufficiency associated with ischemic stroke, psychopathological symptoms associated with aging, transient ischemic attacks.

UR - http://www.scopus.com/inward/record.url?scp=84884015158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884015158&partnerID=8YFLogxK

U2 - 10.1016/B978-008055232-3.63921-2

DO - 10.1016/B978-008055232-3.63921-2

M3 - Chapter

AN - SCOPUS:84884015158

SN - 9780080552323

SP - 1

EP - 18

BT - xPharm: The Comprehensive Pharmacology Reference

PB - Elsevier Inc.

ER -